DRUG
Liraglutide
Participants will receive liraglutide subcutaneously.
Examination of How the Duration of Fasting and Temporary Stopping of GLP-1 Medications Affect the Amount of Food Left in the Stomach in People Using Liraglutide (Injected), Semaglutide (Taken by Mouth) or Semaglutide (Injected)
Status
Recruiting
Phase
Phase 1
Enrollment
71
Locations
1
Results
Not posted
Publications
0
Study summary
What the protocol is testing.
The purpose of this study is to investigate how the duration of fasting and temporary stopping of Glucagon-Like-Peptide 1 (GLP-1) medications affect the amount of food left in the stomach in people using liraglutide (injected), semaglutide (taken by mouth) or semaglutide (injected). The length of participants participation in the study will depend on the type of GLP-1 RA treatment participants are already using.
Interventions
Treatment arms and agents.
DRUG
Oral Semaglutide
Participants will receive semaglutide orally.
DRUG
Semaglutide
Participants will receive semaglutide subcutaneously.
Timeline
From registration to results.
First posted
Nov 10, 2025
Study start
Nov 7, 2025
Primary completion
Dec 13, 2026
Study completion
Jan 6, 2027
Results posted
Not reported
Registry updated
Jul 21, 2026
Outcomes
What the study measures.
Primary outcomes
Occurrence of empty stomach (antrum grade 0 or 1) after fasting following a solid, high-fat meal after dosing of subcutaneous (s.c.) liraglutide once daily (Yes/No)
Time frame · 6, 8, 10, 12, 18 and 24 hours after start of fasting on Visit 7, Day 40
Measured as count of participants.
Occurrence of empty stomach (antrum grade 0 or 1) after fasting following a solid, high-fat meal after dosing of oral semaglutide once daily (Yes/No)
Time frame · 6, 8, 10, 12, 18 and 24 hours after start of fasting on Visit 11, Day 161
Measured as count of participants.
Occurrence of empty stomach (antrum grade 0 or 1) after fasting following a solid, high-fat meal after dosing of s.c. semaglutide once weekly (Yes/No)
Time frame · 6, 8, 10, 12, 18 and 24 hours after start of fasting on Visit 7, Day 141
Measured as count of participants.
Secondary outcomes
Gastric volume after fasting following a solid, high-fat meal after dosing of s.c. liraglutide once daily
Time frame · 6, 8, 10, 12, 18 and 24 hours after start of fasting on Visit 7, Day 40
Measured as milliliters per kilogram (mL/kg).
Gastric volume after fasting following a solid, high-fat meal after dosing of oral semaglutide once daily
Time frame · 6, 8, 10, 12, 18 and 24 hours after start of fasting on Visit 11, Day 161
Measured as mL/kg.
Gastric volume after fasting following a solid, high-fat meal after dosing of s.c. semaglutide once weekly
Time frame · 6, 8, 10, 12, 18 and 24 hours after start of fasting on Visit 7, Day 141
Measured as mL/kg.
Presence of solids in the stomach (antrum grade 'solid') after fasting following a solid, high-fat meal after dosing of s.c. liraglutide once daily (Yes/No)
Time frame · 6, 8, 10, 12, 18 and 24 hours after start of fasting on Visit 7, Day 40
Measured as count of participants.
Presence of solids in the stomach (antrum grade 'solid') after fasting following a solid, high-fat meal after dosing of oral semaglutide once daily (Yes/No)
Time frame · 6, 8, 10, 12, 18 and 24 hours after start of fasting on Visit 11, Day 161
Measured as count of participants.
Presence of solids in the stomach (antrum grade 'solid') after fasting following a solid, high-fat meal after dosing of s.c. semaglutide once weekly (Yes/No)
Time frame · 6, 8, 10, 12, 18 and 24 hours after start of fasting on Visit 7, Day 141
Measured as count of participants.
Occurrence of empty stomach (antrum grade 0 or 1) after fasting following a liquid meal after dosing of s.c. liraglutide once daily (Yes/No)
Time frame · 6, 8, 10, 12, 18 and 24 hours after start of fasting on Visit 7, Day 44
Measured as count of participants
Occurrence of empty stomach (antrum grade 0 or 1) after fasting following a liquid meal after dosing of oral semaglutide once daily (Yes/No)
Time frame · 6, 8, 10, 12, 18 and 24 hours after start of fasting on Visit 11, Day 165
Measured as count of participants.
Occurrence of empty stomach (antrum grade 0 or 1) after fasting following a liquid meal after dosing of s.c. semaglutide once weekly (Yes/No)
Time frame · 6, 8, 10, 12, 18 and 24 hours after start of fasting on Visit 8, Day 148
Measured as count of participants.
Gastric volume after fasting following liquid meal after dosing of s.c. liraglutide once daily
Time frame · 6, 8, 10, 12, 18 and 24 hours after start of fasting on Visit 7, Day 44
Measured as mL/kg
Eligibility
Who can take part.
- Minimum age
- 18 Years
- Maximum age
- Not reported
- Sex
- ALL
- Healthy volunteers
- No
Inclusion Criteria: * Male or female. * Age 18 years or above at the time of signing the informed consent. * BMI between 25.0 and 45 kilogram per meter square (kg/m\^2) (both inclusive) at screening. Overweight should be due to excess adipose tissue, as judged by the investigator. For participants with T2D: * Diagnosed with type 2 diabetes (T2D) more than (\>) 180 days before screening. * Treatment with: 1. no antidiabetic drugs or 2. stable metformin dose or both \[stable dose is defined as the maximum daily tolerated dose for more than or equal to (≥) 90 days before screening\] Exclusion Criteria: * Presence of clinically significant gastrointestinal disorders or symptoms of gastrointestinal disorders potentially affecting absorption of drugs or nutrients, or as judged by the investigator. * History of major surgical procedures involving the oesophagus or stomach potentially affecting absorption of trial products (e.g. subtotal and total gastrectomy, sleeve gastrectomy, gastric bypass surgery) or current presence of gastrointestinal implant. * Diagnosed with or suspected to suffer from clinically significant gastroparesis, hiatal hernia or severe gastro-oesophageal reflux diseases with daily symptoms and/or in supine position. * Use of other medications known to affect the motility of the stomach. * Inability to lie in the right lateral decubitus position for gastric ultrasonography. * Unusual meal habits and special diet requirements or unwillingness to eat the meals provided in the study. For participants without T2D: \- Glycosylated hemoglobin (HbA1c) \> 6.5 percent (%) 48 millimole per mole (mmol/mol) at screening. For participants with T2D: * HbA1c ≥ 10.5 % (91 mmol/mol) at screening. * Current treatment with insulin or insulin secretagogues that might increase risk of hypoglycaemia during periods of fasting. * Recurrent severe hypoglycaemia (more than 1 severe hypoglycaemic event within 180 days) or hypoglycaemic unawareness as judged by the investigator or hospitalisation for diabetic ketoacidosis within 180 days before screening
Study locations
1 registered sites.
United States. Showing up to 24 locations stored in the fast local snapshot.
Altasciences Clinical LA, Inc.
Cypress, California, United States
Publications
Results and literature.
No PMID-linked publications were present in this registry snapshot.
Related trials
More studies on Semaglutide.
NCT IDStudyPhase / statusEnrollmentUpdated
Fibrosis Lessens After Metabolic Surgery
The Cleveland Clinic · Metabolic Dysfunction-associated Steatotic Liver Disease (MASLD) · Non-Alcoholic Fatty Liver Disease
Phase 4
Recruiting
120
2026-07
MODERN-Dental: Pediatric Obesity, Cardiometabolic Risks, And Periodontal Disease
Oelisoa Andriankaja · Obesity · Dental Care for Children
Not applicable
Not yet recruiting
50
2026-07
Semaglutide Delivered Epi-Intradermally by Microarray Patch (VX-201) Versus Subcutaneous Administration in Healthy Overweight and Obese Participants
Terrestrial Bio, Inc. · Overweight and/or Obesity
Phase 1
Recruiting
62
2026-07
Evaluation of the Efficacy and Safety of Tirzepatide, a Dual GLP-1/GIP Agonist, on Functional Capacity in Reduced Ejection Fraction Heart Failure Patients With Obesity
Shahid Beheshti University of Medical Sciences · Heart Failure and Reduced Ejection Fraction · Obesity & Overweight
Phase 3
Not yet recruiting
60
2026-07
Tirzepatide Impact Assessment Study
Texas Tech University · Obesity & Overweight · Cardiometabolic Health Indicators
Not applicable
Recruiting
27
2026-07
A Study of HRS9531 Versus Semaglutide Once Weekly as Add-on Therapy to Metformin Monotherapy or in Combination With SGLT2 Inhibitors in Participants With Type 2 Diabetes
Fujian Shengdi Pharmaceutical Co., Ltd. · Type 2 Diabetes
Phase 3
Completed
884
2026-07
A Research Study to Look at How Two Different Doses of CagriSema and One Dose of Semaglutide Help People Living With Obesity With or Without Type 2 Diabetes Lose Weight
Novo Nordisk · Obesity · Type 2 Diabetes
Phase 3
Recruiting
2,500
2026-07
Tirzepatide Following Adrenalectomy in Mild Autonomous Cortisol Secretion
Alaa Sada · Mild Autonomous Cortisol Secretion (MACS) · Adrenalectomy; Status
Phase 2
Recruiting
34
2026-07
Related PeptideStat pages
Put the record in context.
Research pages describe evidence. Vendor pages, where available, describe independently tracked research-product listings and are not clinical recommendations.
TrialsSemaglutide trial dashboard →DatabaseSemaglutide database entry →ResearchSemaglutide research guide →TrialsLiraglutide trial dashboard →DatabaseLiraglutide database entry →ResearchLiraglutide research guide →TrialsGlucagon trial dashboard →DatabaseGlucagon database entry →ResearchGlucagon research guide →